Amylyx Pharmaceuticals, Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024. Amylyx is a biotechnology company developing treatments for neurodegenerative diseases. Unless otherwise noted, financial amounts are in U.S. dollars.
Financial results and liquidity
| Metric | Q1 2024 | Q1 2023 / comparison |
|---|---|---|
| Net product revenue | $88.6 million | $71.4 million; up 24% |
| Cost of sales, including inventory impairment and purchase-commitment loss | $116.4 million | $5.3 million |
| Research and development | $36.6 million | $24.2 million; up 51% |
| Selling, general and administrative | $57.8 million | $44.0 million; up 31% |
| Operating loss | $122.1 million | $2.1 million |
| Net loss (income) | $118.8 million loss | $1.6 million income |
| Net loss per share | $1.75 | $0.02 income per share |
| Cash used in operating activities | $0.5 million | $5.1 million |
The reported cost-of-sales charge of $110.5 million included approximately $92.5 million for inventory write-downs and $17.9 million for firm purchase commitments, following the decision to withdraw RELYVRIO/ALBRIOZA. These unusual charges drove the quarterly loss and overwhelmed revenue; reported operating results should be read in that context.
At March 31, 2024, cash and cash equivalents were $170.6 million and short-term investments were $202.7 million, totaling $373.3 million. Total assets were $417.5 million, compared with $517.5 million at year-end 2023. Current assets were $410.5 million and current liabilities $91.6 million. The company reported no borrowings; liabilities primarily included accrued expenses, accounts payable and operating leases. Inventory was reduced to zero after the write-down.
Operating cash use was low relative to the net loss largely because the inventory and purchase-commitment charges were noncash in the quarter. Cash, cash equivalents and restricted cash increased $0.4 million to $171.3 million; investment purchases and maturities largely offset each other. The filing does not provide a clear operating margin excluding the unusual charges.
Material developments and outlook
- RELYVRIO/ALBRIOZA withdrawal: On April 4, 2024, after the Phase 3 PHOENIX trial failed to meet its prespecified primary and secondary endpoints, Amylyx announced a process with FDA and Health Canada to voluntarily discontinue marketing authorizations and remove the ALS product from the U.S. and Canadian markets. It was no longer available to new patients as of that date; existing patients wishing to continue may transition to a free-drug program in consultation with their physicians. The company expects no future product revenue from these sales.
- Restructuring: Announced in April, the plan targets an approximately 70% workforce reduction and lower external commitments outside priority programs. Amylyx expects about $19.1 million in severance and related charges and expects substantial completion by the end of Q3 2024. It expects SG&A to decline in 2024, while noting implementation costs and operational risks.
- Cash runway: Management believes March 31 cash, cash equivalents and short-term investments will fund anticipated operating and capital needs for at least 12 months after the filing date. This estimate depends on assumptions and could prove incorrect; additional capital may be needed.
- Development programs: AMX0035’s Phase 2 HELIOS trial in Wolfram syndrome (WS) reported preliminary interim results for eight participants completing 24 weeks, with management describing early improvements in glucose-control, visual-acuity and disease-burden measures. The open-label interim findings are preliminary; topline results for all 12 participants at Week 24 were anticipated in fall 2024. The Phase 3 ORION trial in progressive supranuclear palsy (PSP) continued, with interim data expected in mid-2025. Amylyx planned to file an IND and start a multiple-ascending-dose AMX0114 trial in ALS in the second half of 2024.
- Commitments and legal matter: Estimated manufacturing and raw-material commitments were approximately $35.1 million, expected through 2025, down from approximately $195.0 million reported at year-end 2023; estimates may change. A putative securities class action alleges misleading statements about RELYVRIO’s commercial results and prospects. The company intends to defend the case; the potential financial impact cannot currently be estimated.
Key investor verification points
- Track regulatory completion and practical effects of the U.S. and Canadian withdrawal, including patient access, returns and any remaining supplier obligations.
- Assess the restructuring’s actual headcount, cash costs, savings, and impact on the execution of clinical programs.
- Review final HELIOS data against the small, open-label interim analysis, and monitor ORION enrollment, trial progress and interim results.
- Confirm AMX0114 IND timing and clinical-trial initiation, and whether the cash-runway assumptions remain achievable without new financing.
- Monitor changes to manufacturing commitments, accrued liabilities, cash burn and the securities litigation as further information becomes available.